1 The effect of L-NG-nitro arginine (L-NOARG) was compared with that of L-NG-monomethyl arginine (L-NMMA) on vasodilatation of the isolated aorta of the rabbit and perfused mesentery of the rat in response to acetylcholine (ACh) and sodium nitroprusside (NP). 2 L-NOARG (1.5-100Mm) and L-NMMA (3-100Mm) produced concentration-related contraction of the rabbit aorta precontracted with phenylephrine (700-900nM). Similarly, L-NOARG (10-2001pM) and L-NMMA (30-100 gM) elevated perfusion pressure of the noradrenaline (NA, 0.6-2.5mM)-preconstricted rat mesentery preparation. 6 These results identify L-NOARG as a potent, L-arginine reversible inhibitor of endothelium-dependent vasodilatation. The available data suggests that L-NOARG, like L-NMMA, inhibits endothelial nitric oxide (NO) biosynthesis.
Contraction of smooth muscle is initiated, and to a lesser extent maintained, by a rise in the concentration of free calcium in the cell cytoplasm ([Ca 2+ ] i ). This activator calcium can originate from two intimately linked sources ± the extracellular space and intracellular stores, most notably the sarcoplasmic reticulum. Smooth muscle contraction activated by excitatory neurotransmitters or hormones usually involves a combination of calcium release and calcium entry. The latter occurs through a variety of calcium permeable ion channels in the sarcolemma membrane. The bestcharacterized calcium entry pathway utilizes voltage-operated calcium channels (VOCCs). However, also present are several types of calcium-permeable channels which are non-voltage-gated, including the so-called receptor-operated calcium channels (ROCCs), activated by agonists acting on a range of G-protein-coupled receptors, and store-operated calcium channels (SOCCs), activated by depletion of the calcium stores within the sarcoplasmic reticulum. In this article we will review the electrophysiological, functional and pharmacological properties of ROCCs and SOCCs in smooth muscle and highlight emerging evidence that suggests that the two channel types may be closely related, being formed from proteins of the Transient Receptor Potential Channel (TRPC) family.
The effects of L-NG-nitro arginine (L-NOARG) on a-chymotrypsin-resistant, non-adrenergic, noncholinergic (NANC) relaxations of guinea-pig tracheal smooth muscle have been examined. L-NOARG (1-100pM), but not D-NOARG (100pM), inhibited the NANC relaxations in a concentration-related manner. The effects of L-NOARG were partially reversed by L-arginine but not D-arginine. L-NOARG was without effect on acetylcholine-induced contractile responses of the trachea or on relaxations produced by vasoactive intestinal peptide, sodium nitroprusside or isoprenaline. These results suggest that an endogenous nitrate may contribute to NANC relaxations of tracheal smooth muscle.Introduction In many species, including man and guinea-pig, electrically induced relaxations of tracheal smooth muscle have a non-adrenergic, non-cholinergic (NANC) component (Barnes, 1986). The identity of the neurotransmitter which mediates this effect is unknown and may vary with the species studied. In the guinea-pig, vasoactive intestinal peptide (VIP) and peptide histidine isoleucine (PHI) are strong candidates for at least part of this NANC relaxant response. Ellis &
1 By use of the whole-cell configuration of the patch-clamp technique, membrane currents induced by cyclopiazonic acid (CPA; an inhibitor of the sarcoplasmic reticulum (SR) calcium-ATPase) were investigated in single smooth muscle cells freshly dispersed from the mouse anococcygeus. Voltagedependent calcium currents were blocked with extracellular nifedipine and caesium and tetraethylammonium chloride were used to block voltage-dependent potassium currents. 2 At a holding potential of -40 mV, CPA (10 tiM) activated an inward current that consisted of two distinct components. The first was an initial transient current with an amplitude of 19.6 + 1.9 pA while the second was sustained and had an amplitude of 3.5 + 0.3 pA. 3 The current-voltage (I-V) relationship for the transient current showed marked outward rectification. The current had a reversal potential of 9.1 + 1.1 mV which was shifted to 29.0 + 4.2 mV when the extracellular chloride concentration was lowered from 148.4 to 58.4 mM. The sustained current had a near-linear I-V relationship and a reversal potential of 31.0+2.7 mV. Removal of extracellular calcium had no effect on the transient current, but shifted the reversal potential of the sustained current to 18.2+ 5.7 mV. 3 The initial transient current was abolished in cells bathed in extracellular solutions containing the chloride channel blockers, 4,4' diisothiocyanato-stilbene-2,2'-disulphonic acid (DIDS; 1 mM) or anthracene-9-carboxylic acid (A-9-C; 1 mM), and was absent in cells containing the calcium buffers EGTA (1 to 5 mM) or BAPTA (10 mM). The second sustained current was unaffected by either the chloride channel blockers or the intracellular calcium buffers. 4 Treatment of the cells with caffeine (10 mM) produced similar inward currents to those produced by CPA. In the presence of caffeine, CPA (10 gM) induced no further inward current. 5 In organ bath studies, CPA (10 gM)-induced contractions of the mouse anococcygeus were inhibited by cadmium and nickel (both 50-400 uM) and the general calcium entry blocker, SKF 96365 (10 gM); lanthanum and gadolinium had no effect at concentrations up to 400 gM. The pharmacology of the CPA-induced non-selective cation current mirrored that of the CPA-induced whole muscle contraction being reversed by cadmium (100 tM) and SKF 96365 (10 uM), but unaffected by lanthanum (400 gM).The initial chloride conductance was unaffected by cadmium, SKF 96365 or lanthanum. 6 It is concluded that CPA activates a transient calcium-dependent chloride current as a consequence of calcium release from intracellular stores; this current would result in depolarization and opening of voltage-operated calcium channels, which mediate the nifedipine-sensitive component of muscle contraction. In addition, as a result of emptying the SR, CPA activates a non-selective cation conductance which may underlie the nifedipine-insensitive calcium entry process utilised during sustained contraction.
6LX1 The aim of this study was to determine whether the fish neuropeptide, Gillichthys urotensin II (GUII), possesses significant biological activity on rat aortic strips. 2 On intact strips, pre-contracted by noradrenaline (100 nM), low concentrations (0.1-0.5 nM) of GUII produced relaxations, while higher concentrations (1-10 nM) caused further contraction. On strips rubbed to remove endothelial cells, relaxations were absent but contractile responses to higher concentrations of GUII remained. 3 GUII (0.2-10nM) produced dose-related contractions of quiescent, intact aortic strips. These contractions consisted of two components, tonic and phasic, and were potentiated in rubbed strips and in the presence of the antioxidant drug hydroquinone (1O iM).4 Mepacrine (40 jM) and p-bromophenacyl bromide (50 gM) completely abolished contractions to GUII, but indomethacin (10 jM) and nordihydro-guaiaretic acid (1I0 M) were without effect. 5 The phasic, but not the tonic, component of the contractile response was inhibited by nitrendipine (200 nM), and was absent in bathing medium from which Ca2' had been omitted. Addition of EGTA (2 mM) to Ca2+-free bathing medium abolished the residual tonic component. 6 GUII-induced contractions were completely abolished by the calmodulin antagonists trifluoperazine (50 pM) and W-7 (30 gM).7 It is concluded that GUII, previously considered devoid of significant activity on mammalian tissues, produces potent endothelium-dependent relaxations and endothelium-independent contractions of rat aorta, and possible mechanisms underlying each response are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.